Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Brokerages

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) have been given an average recommendation of “Buy” by the five analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a strong buy rating to the company.

Several analysts recently commented on the company. HC Wainwright raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday, December 26th. Lifesci Capital raised Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Zacks Research upgraded Inhibikase Therapeutics to a “hold” rating in a research note on Tuesday, December 2nd. Wall Street Zen upgraded shares of Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday.

Inhibikase Therapeutics Price Performance

IKT opened at $1.74 on Wednesday. The firm’s 50 day moving average is $1.67. Inhibikase Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.32. The stock has a market capitalization of $130.81 million, a PE ratio of -4.46 and a beta of 0.84.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.